scholarly journals The Impact of Metabolic Syndrome and Its Components on Female Sexual Dysfunction: A Narrative Mini-Review

2018 ◽  
Vol 12 (2) ◽  
pp. 57-63
Author(s):  
Simona Di Francesco ◽  
Marika Caruso ◽  
Iole Robuffo ◽  
Andrea Militello ◽  
Elena Toniato
Keyword(s):  
Diabetes Mellitus ◽  
Metabolic Syndrome ◽  
Sexual Dysfunction ◽  
Arterial Hypertension ◽  
Sexual Function ◽  
Sexual Desire ◽  
Female Sexual Dysfunction ◽  
Systemic Arterial Hypertension ◽  
The Metabolic Syndrome ◽  
The Impact

Background: The impact of metabolic syndrome on female sexual dysfunction received modest consideration in clinical practice. The aim of the research was to analyze the international literature to determine the relationship between the metabolic syndrome, its components and female sexual disorders. Methods: We identified relevant full-length papers by electronic databases as Index Medicus/Medline, Scopus, Life Science Journals, from 2005 to the present. Studies were searched using the following as search query: metabolic syndrome, female sexual dysfunction, obesity, systemic arterial hypertension, diabetes mellitus, dyslipidemia. Results: Women with metabolic syndrome showed higher prevalence of sexual inactivity and low sexual desire, orgasm and satisfaction respect to women without metabolic syndrome. Particularly metabolic components as diabetes mellitus, dy-slipidemia, systemic arterial hypertension were strongly associated with lower sexual desire, activity and Female Sexual Function Index total score. In contrast, other studies showed no relationship. Conclusion: Our study showed that in the clinical evaluation of women with metabolic syndrome routine inquiring about female sexual dysfunction should be recommended to ameliorate sexual function and quality of life. However more prospective and longitudinal studies on the sexual effects of metabolic syndrome should also be suggested to know the factors related to women's sexuality better.

scholarly journals Can a high visceral adiposity index predict female sexual dysfunction in sexually active women? Results of a cross-sectional study.

2021 ◽  
Author(s):  
Ramazan Aşçı ◽  
Mustafa Bolat ◽  
Cihad Dündar ◽  
Ayse Zehra Ozdemir ◽  
Aysegul Atmaca
Keyword(s):  
Metabolic Syndrome ◽  
Sexual Dysfunction ◽  
Sexual Function ◽  
Female Sexual Dysfunction ◽  
Visceral Adiposity ◽  
Visceral Adiposity Index ◽  
Female Sexual Function ◽  
Cross Sectional ◽  
Adiposity Index ◽  
The Impact

Aims: To our knowledge, this is the first study investigating the impact of high visceral adiposity index on female sexual dysfunction (FSD). We aimed to show the impact of increased levels of visceral adiposity index (VAI) on FSD compared to body mass index (BMI) and waist circumference (WC). Methods: We included 158 participants in two groups: Group 1 (n=68 with normal sexual function) and Group 2 (n=90 with sexual dysfunction). Demographic, clinic data, presence of metabolic syndrome (MeTS) and comorbidities were recorded. The BMI, WC and the visceral adiposity index were calculated. Sexual function was assessed using the female sexual function index (FSFI). Results: The mean age and all the anthropometric variables were similar between the groups (p>0.05). Metabolic syndrome was associated with lower arousal and lubrication scores than those without metabolic syndrome (p=0.023). The higher VAI was associated with lower desire, lubrication and orgasm scores (p<0.05). Each integer increase of the VAI weakly predicted decrease of desire (p=0.015), arousal (p=0.015), lubrication (p=0.005) and satisfaction (p=0.046). Conclusion: The VAI was linked with lower scores in some female sexual function subdomains, but the correlation coefficient was low, indicating a weak association. Further studies with a higher number of participants are needed to conclude that the VAI may increase the risk of FSD, particularly in patients with metabolic syndrome.

Impact of Individual Components of the Metabolic Syndrome on the Outcome of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib

2017 ◽  
Vol 36 (1) ◽  
pp. 78-88 ◽  
Author(s):  
Christian Labenz ◽  
Vera Prenosil ◽  
Sandra Koch ◽  
Yvonne Huber ◽  
Jens U. Marquardt ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Hepatocellular Carcinoma ◽  
Metabolic Syndrome ◽  
Group Performance ◽  
Performance Status ◽  
Eastern Cooperative Oncology Group ◽  
Advanced Hepatocellular Carcinoma ◽  
Advanced Hcc ◽  
The Metabolic Syndrome ◽  
The Impact

Background/Aim: Individual components of the metabolic syndrome (MS) such as obesity or diabetes mellitus impair the prognosis of patients with hepatocellular carcinoma (HCC) following curative treatment approaches or transarterial therapies. The aim of this retrospective study was to assess the impact of these factors on the overall survival (OS) of patients with advanced HCC treated with sorafenib. Methods: Univariate and multivariate analyses were performed to assess the impact of individual components of the MS on the OS of 152 consecutive patients with advanced HCC treated with sorafenib. Results: The presence of overweight/obesity, type 2 diabetes mellitus, hypertension, dyslipidemia, and of the MS itself did not impair the median OS. Multivariate analysis showed that Eastern Cooperative Oncology Group Performance Status ≥1 (hazards ratio [HR] 2.03), presence of macrovascular invasion (HR 1.71), Child-Pugh score B/C (HR 2.19), tumor grading G3 (HR 2.17), no prior HCC treatment (HR 2.34), and the presence of 2 or more out of 5 individual components of the MS (HR 0.65) were independent prognostic factors regarding the median OS. Conclusions: Our investigations do not confirm a negative prognostic role of individual components of the MS or the MS itself for patients with advanced HCC treated with sorafenib.

scholarly journals A szexuális funkciózavar és a metabolikus szindróma kapcsolata

2019 ◽  
Vol 160 (3) ◽  
pp. 98-103 ◽  
Author(s):  
Márta Zsoldos ◽  
Attila Pajor ◽  
Henriette Pusztafalvi
Keyword(s):  
Diabetes Mellitus ◽  
Insulin Resistance ◽  
Type 2 Diabetes ◽  
Metabolic Syndrome ◽  
Sexual Dysfunction ◽  
The Metabolic Syndrome ◽  
Atherogenic Lipid Profile ◽  
Arousal Response ◽  
Atherogenic Lipid

Abstract: The prevalence of the metabolic syndrome, type 2 diabetes mellitus, cardiovascular diseases, obesity and depression have increased during the recent years. As the sexual dysfunction is also frequent, we aimed to search for the associations between sexual dysfunction and the metabolic syndrome and its components, respectively, by reviewing the literature. The clinical and biochemical components of the metabolic syndrome included cardiovascular disease, type 2 diabetes mellitus, visceral obesity and depression, furthermore, insulin resistance, atherogenic lipid profile, hypogonadism, chronic systemic inflammation and endothelial dysfunction were all demonstrated to affect adversely the sexual function. The dysfunction of the sexual arousal response shows a strong association in men and a milder one in women with the cardiovascular diseases and depression. Sexual function in diabetes mellitus is mostly impaired by microvascular injury, polyneuropathy and autonomic neuropathy. Erectile dysfunction and disorder of the female sexual arousal response and the orgasm, respectively, are associated with insulin resistance, atherogenic lipid profile and systemic inflammatory condition in overweight or obese patients. Sexual dysfunction particularly in men can be an early sign of the severe complications of metabolic syndrome. The pathogenetic link between the metabolic syndrome and the sexual dysfunction seems to be the insulin resistance. Both metabolic syndrome and sexual dysfunction can be restored by altering the lifestyle. Orv Hetil. 2019; 160(3): 98–103.

scholarly journals Depression, Anxiety and Sexual Dysfunction Among Jordanian Women With Type 2 Diabetes Mellitus

2020 ◽  
Author(s):  
Zaina Alazawi ◽  
Ola Alqudah ◽  
Ahmad Al-Bashaireh
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Sexual Dysfunction ◽  
Sexual Function ◽  
Female Sexual Dysfunction ◽  
Female Sexual Function Index ◽  
Female Sexual Function ◽  
Arabic Version

The aims of this study are to determine the prevalence of sexual dysfunction and to examine the relationships of sexual function and psychological factors of depression and anxiety and diabetes-related factors in Jordanian women with type 2 diabetes mellitus. This study employed a cross-sectional, descriptive, correlational design. All eligible participants with type 2 diabetes mellitus were consequently recruited from primary care centers. All enrolled participants were asked to complete questionnaires: Arabic version of the Female Sexual Function Index, Beck Depression Inventory-II, Beck Anxiety Inventory, and demographic questionnaires. Physical and biological measures were collected from the patient's medical records. 107 women with type 2 diabetes mellitus were recruited with a mean of age of 52.46±8.38 years. The prevalence of female sexual dysfunction was 94.4%. Regarding the mean scores of the Arabic version of the Female Sexual Function Index domains, the highest mean score was for pain (5.09±1.51), and the lowest mean score was for sexual arousal (2.44±1.28). This study found significant inverse relationships between female sexual function and age (r= -0.340, P<0.01), duration of diabetes (r= -0.211, P=0.029), fasting blood sugar (r= -0.234, P=0.015), anxiety (r= -0.375, P<0.01), and depression (r= -0.480, P<0.01). Our study found female sexual dysfunction is widely prevalent in Jordanian women with type 2 diabetes mellitus (94.4%). There were significant correlations between anxiety, depression, and female sexual function among women with type 2 diabetes mellitus.

Drug therapy and nutritional management of metabolic syndrome associated with hyperadrenocorticism in a dog – case report

2017 ◽  
Vol XXII (131) ◽  
pp. 38-46
Author(s):  
Viviani De Marco ◽  
Elidia Zotelli dos Santos
Keyword(s):  
Insulin Resistance ◽  
Metabolic Syndrome ◽  
Arterial Hypertension ◽  
Systemic Arterial Hypertension ◽  
The Metabolic Syndrome ◽  
Generic Term ◽  
High Concentrations ◽  
Stable Control ◽  
Biochemical Abnormalities

Hyperadrenocorticism (HAC) is a generic term that refers to clinical and biochemical abnormalities resulting from persistently high concentrations of glucocorticoids in the bloodstream, which may occur spontaneously or iatrogenically. Chronic hypercortisolism may promote abdominal obesity, dyslipidemia, systemic arterial hypertension and insulin resistance, abnormalities associated with the metabolic syndrome (MS). The present study aims to report the presence of MS in a dog with spontaneous HAC, and its satisfactory long-term therapeutic resolution. The animal presented marked alterations in addition to the classic symptoms of HAC: discrete hyperglycemia, insulin resistance, hyperlipidemia, arterial hypertension and obesity. Complete resolution of MS and stable control of HAC were observed after five months of treatment.

The impact of female sexual dysfunction on male sexual function: A cross sectional study

2017 ◽  
Vol 16 (13) ◽  
pp. e3021
Author(s):  
A. Zachariou ◽  
M. Filiponi ◽  
F. Dimitriadis ◽  
I. Giannakis ◽  
P. Lantin ◽  
...  
Keyword(s):  
Sexual Dysfunction ◽  
Sexual Function ◽  
Female Sexual Dysfunction ◽  
Cross Sectional Study ◽  
Sectional Study ◽  
Cross Sectional ◽  
Male Sexual Function ◽  
The Impact

The Impact of Minimally Invasive Pituitary Surgery on Male and Female Sexual Dysfunction in Patients with Pituitary Adenoma

2021 ◽  
pp. 1-7
Author(s):  
Aydin Talat Baydar ◽  
Ali Yasin Ozercan ◽  
Denizhan Divanlioglu ◽  
Zeynep Daglar ◽  
Melih Balci ◽  
...  
Keyword(s):  
Pituitary Adenoma ◽  
Sexual Dysfunction ◽  
Minimally Invasive ◽  
Sexual Function ◽  
Pituitary Adenomas ◽  
Female Sexual Dysfunction ◽  
Pituitary Surgery ◽  
Male And Female ◽  
Female Patients ◽  
The Impact

<b><i>Introduction:</i></b> In the present study, we prospectively investigated the impact of endoscopic transnasal trans-sphenoidal surgery (ETTS) on sexual function in male and female patients with pituitary adenoma. <b><i>Methods:</i></b> The study included a total of 40 consecutive patients (male, <i>n</i> = 28 and female, <i>n</i> = 12) aged 22–65 years, who underwent ETTS for pituitary adenoma in our center between March 2019 and August 2019. Twenty-seven (67.5%) and 13 (32.5%) patients had functioning and nonfunctioning pituitary adenomas, respectively. Routine preoperative hormone levels were obtained in every patient. The tests were repeated at the postoperative third month. Preoperatively and at the postoperative third month, the 5-item version of the International Index of Erectile Function and the Female Sexual Function Index (FSFI) was used in male and female patients, respectively. <b><i>Results:</i></b> Before surgery, 24 (85.7%) men had erectile dysfunction (ED), and 10 (83%) women had female sexual dysfunction. After surgery, all the patients’ abnormal hormone parameters improved. All the male patients’ ED degrees were positively affected by surgery. In women, the FSFI was significantly better than in the preoperative period. <b><i>Discussion/Conclusion:</i></b> Our results showed that both males and females with pituitary adenomas benefitted from minimally invasive pituitary surgery in terms of a high-remission rate and improvement in sexual dysfunction.

scholarly journals High visceral adiposity index associated with metabolic syndrome impairs erectile function in sexually active men.

2020 ◽  
Author(s):  
Mustafa Bolat ◽  
Mustafa Latif Özbek ◽  
Bekir Şahin ◽  
Merve YILMAZ ◽  
Fatih Kocamanoğlu ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Sexual Function ◽  
Erectile Function ◽  
Visceral Adiposity Index ◽  
Characteristic Analysis ◽  
The Metabolic Syndrome ◽  
Increased Risk ◽  
Group 2 ◽  
The Impact ◽  
Group 1

Aims:Erectile dysfunction (ED) is a common condition affected by many factors. We aimed to show the impact of the metabolic syndrome (MeTS) on male sexual function based on VAI and the impact of increased levels of the VAI was investigated in patients with ED among the patients with and without MeTS. Methods:Participants who met MeTS criteria (Group 1, n=96) and without MeTS (Group 2, n=189) were included in this cross-sectional study. The MeTS diagnosis was made in the presence of at least three of the following criteria: serum glucose level higher than 100 mg/dl, HDL cholesterol level below 40 mg/dl, triglyceride level greater than 150 mg/dl, waist circumference greater than 102 cm and blood pressure greater than 130/85 mmHg. Demographic data were recorded; biochemical and hormonal tests were measured. Erectile and other sexual function scores were recorded. The VAI was calculated using the [(WC/39.68)+(1.88xMI)]xTG/1.03x1.31/HDL formula. Results:Mean age, smoking volume, T and T/E2 ratios of the groups were similar (p>0.05). Mean VAI was two-fold higher in patients in Group 1 (p<0.001) and erectile function score was lower in Group 1 than Group 2 (p=0.001). Other sexual function scores were similar (p>0.05). The METS was associated with an increased risk of ED (p=0.001). Logistic regression analysis showed that each integer increase of the VAI was associated with a 1.4-fold increased risk of ED (p<0.001). Higher T values were associated with a better erectile function (p=0.03). For the VAI=4.33, receiver-operating characteristic analysis showed a sensitivity of 89.6 % and specificity of 57.7 %. Conclusion:Compared to non-MeTS, the presence of MeTS has emerged as a risk factor for patients with ED with high VAI levels while the other sexual functions are preserved. Management of ED patients with MeTS should cover a comprehensive metabolic and endocrinological evaluation in addition to andrological work up.

Sign in / Sign up

Export Citation Format

Share Document